VK-2735

Viking Therapeutics is advancing its oral dual GLP-1/GIP agonist VK2735 into Phase 2 clinical trials, marking a significant step in developing a potential new treatment option for obesity.

Amgen executives defended MariTide's clinical profile at JPM25, highlighting its potential for less frequent dosing and comparable weight loss to existing drugs.

Viking Therapeutics has commenced a Phase 2 clinical trial for oral VK2735, a dual GLP-1/GIP agonist, to treat obesity.

Altimmune's pemvidutide, currently in Phase II trials for obesity and metabolic dysfunction-associated steatohepatitis, is projected to reach $1.21 billion in sales by 2030.

The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity.